Answer
During Uvadex (methoxsalen) photopheresis, patients with co-existing basal cell carcinoma, squamous cell carcinoma or malignant melanoma should be monitored for any changes in their skin cancer, although there is no evidence of increased risk of these cancers with extracorporeal Uvadex.
Sources for this answer
- UVADEX 20 micrograms/ml Solution for Blood Fraction ModificationTherakos (UK) Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked